Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 03, 2022

SELL
$223.92 - $287.77 $158,983 - $204,316
-710 Closed
0 $0
Q3 2021

Jun 02, 2022

BUY
$282.99 - $369.05 $200,922 - $262,025
710 New
710 $201,000
Q3 2021

Nov 03, 2021

SELL
$282.99 - $369.05 $200,922 - $262,025
-710 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$259.0 - $414.71 $15,540 - $24,882
-60 Reduced 7.79%
710 $246,000
Q1 2021

May 11, 2021

BUY
$242.95 - $284.63 $187,071 - $219,165
770 New
770 $215,000
Q4 2020

Feb 01, 2021

SELL
$236.26 - $355.63 $214,996 - $323,623
-910 Closed
0 $0
Q2 2020

Aug 07, 2020

BUY
$258.66 - $342.55 $5,431 - $7,193
21 Added 2.36%
910 $243,000
Q1 2020

Apr 30, 2020

SELL
$268.85 - $341.04 $26,885 - $34,104
-100 Reduced 10.11%
889 $281,000
Q4 2019

Jan 29, 2020

SELL
$220.06 - $304.07 $77,021 - $106,424
-350 Reduced 26.14%
989 $293,000
Q3 2019

Oct 28, 2019

SELL
$217.44 - $243.88 $10,872 - $12,194
-50 Reduced 3.6%
1,339 $312,000
Q2 2019

Jul 31, 2019

SELL
$219.29 - $241.72 $76,751 - $84,602
-350 Reduced 20.13%
1,389 $325,000
Q1 2019

Apr 29, 2019

SELL
$216.71 - $338.96 $32,506 - $50,844
-150 Reduced 7.94%
1,739 $411,000
Q4 2018

Jan 28, 2019

SELL
$278.5 - $352.75 $167,100 - $211,650
-600 Reduced 24.11%
1,889 $568,000
Q3 2018

Nov 09, 2018

SELL
$293.51 - $383.83 $5,870 - $7,676
-20 Reduced 0.8%
2,489 $879,000
Q1 2018

May 03, 2018

SELL
$260.13 - $367.91 $33,036 - $46,724
-127 Reduced 4.82%
2,509 $687,000
Q4 2017

Feb 12, 2018

SELL
$307.64 - $344.58 $52,298 - $58,578
-170 Reduced 6.06%
2,636 $840,000
Q3 2017

Nov 13, 2017

SELL
$281.15 - $329.69 $16,869 - $19,781
-60 Reduced 2.09%
2,806 $879,000
Q2 2017

Aug 09, 2017

BUY
N/A
2,866
2,866 $778,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Sheaff Brock Investment Advisors, LLC Portfolio

Follow Sheaff Brock Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sheaff Brock Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sheaff Brock Investment Advisors, LLC with notifications on news.